168 related articles for article (PubMed ID: 16931453)
1. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
Gorden P; Park JY
Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
[TBL] [Abstract][Full Text] [Related]
2. The clinical uses of leptin.
Gorden P; Gavrilova O
Curr Opin Pharmacol; 2003 Dec; 3(6):655-9. PubMed ID: 14644019
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of leptin therapy in metabolic dysfunction.
Park JY; Gavrilova O; Gorden P
Minerva Endocrinol; 2006 Jun; 31(2):125-31. PubMed ID: 16682936
[TBL] [Abstract][Full Text] [Related]
4. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
5. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
6. Rethinking leptin and insulin action: therapeutic opportunities for diabetes.
Yildiz BO; Haznedaroglu IC
Int J Biochem Cell Biol; 2006; 38(5-6):820-30. PubMed ID: 16236542
[TBL] [Abstract][Full Text] [Related]
7. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency.
McDuffie JR; Riggs PA; Calis KA; Freedman RJ; Oral EA; DePaoli AM; Yanovski JA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4258-63. PubMed ID: 15356018
[TBL] [Abstract][Full Text] [Related]
8. Leptin-replacement therapy for lipodystrophy.
Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
[TBL] [Abstract][Full Text] [Related]
9. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
DePaoli AM
J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
[TBL] [Abstract][Full Text] [Related]
10. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
[TBL] [Abstract][Full Text] [Related]
11. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
[TBL] [Abstract][Full Text] [Related]
12. Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.
Miyamoto L; Ebihara K; Kusakabe T; Aotani D; Yamamoto-Kataoka S; Sakai T; Aizawa-Abe M; Yamamoto Y; Fujikura J; Hayashi T; Hosoda K; Nakao K
J Biol Chem; 2012 Nov; 287(48):40441-7. PubMed ID: 23024365
[TBL] [Abstract][Full Text] [Related]
13. Metreleptin treatment of non-HIV lipodystrophy syndromes.
Chevalier B; Lemaitre M; Leguier L; Mapihan KL; Douillard C; Jannin A; Espiard S; Vantyghem MC
Presse Med; 2021 Nov; 50(3):104070. PubMed ID: 34571177
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function.
Bruder-Nascimento T; Kress TC; Belin de Chantemele EJ
F1000Res; 2019; 8():. PubMed ID: 31656583
[TBL] [Abstract][Full Text] [Related]
15. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.
Rodríguez AJ; Neeman T; Giles AG; Mastronardi CA; Paz Filho G
Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):783-97. PubMed ID: 25465598
[TBL] [Abstract][Full Text] [Related]
16. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
17. Leptin in the treatment of lipodystrophy-associated nonalcoholic fatty liver disease: are we there already?
Machado MV; Cortez-Pinto H
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):513-5. PubMed ID: 23985000
[TBL] [Abstract][Full Text] [Related]
18. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
[TBL] [Abstract][Full Text] [Related]
19. Hypothalamic melanocortin signaling and leptin resistance--perspective of therapeutic application for obesity-diabetes syndrome.
Masuzaki H; Tanaka T; Ebihara K; Hosoda K; Nakao K
Peptides; 2009 Jul; 30(7):1383-6. PubMed ID: 19394382
[TBL] [Abstract][Full Text] [Related]
20. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
